Hsin-Ell Wang

Title: Hsin-Ell Wang: Innovator in Targeted Drug Delivery Systems

Introduction

Hsin-Ell Wang is a prominent inventor based in Taoyuan County, Taiwan. He has made significant contributions to the field of targeted drug delivery systems, holding a total of 5 patents. His innovative work focuses on developing advanced therapeutic solutions for cancer treatment.

Latest Patents

One of Hsin-Ell Wang's latest patents is the "Targeted prodrug cytosine deaminase fusion carrier and application thereof." This invention provides a targeted prodrug enzyme fusion carrier that effectively identifies and binds to tumor cells and tumor-induced angiogenesis. The carrier includes a targeted prodrug enzyme fusion protein and a theranostic system that utilizes in vivo nuclear medicine for the clinical diagnosis and treatment of individual patients with tumors.

Another notable patent is the "Dual targeting drug carrier and application thereof." This dual targeting drug carrier comprises a first and a second targeting molecule, which can be peptides, proteins, or antibodies. These targeting molecules bind to specific receptors or proteins to recognize particular tumor cells, tissues, or organs. The dual targeting drug carriers are further conjugated with imaging agents, radioactive molecules, or nanoparticles to form a conjugate.

Career Highlights

Hsin-Ell Wang has worked at esteemed institutions such as National Yang Ming Chiao Tung University and the Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan. His work at these organizations has allowed him to advance his research and contribute to the field of nuclear medicine and targeted therapies.

Collaborations

Hsin-Ell Wang has collaborated with notable colleagues, including Hao-Wen Kao and Wuu-Jyh Lin. These collaborations have fostered innovation and development in the area of targeted drug delivery systems.

Conclusion

Hsin-Ell Wang's contributions to the field of targeted drug delivery systems are noteworthy. His innovative patents and collaborations highlight his commitment to advancing cancer treatment technologies. His work continues to pave the way for more effective therapeutic solutions for patients.